Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
Tel: +86-173-20513646
Mobile: 17320513646
Tel: +86-173-20513646
Fax:
Province/state: Hu Bei
City: Wuhan
Street: Company address: Room 005, 15th Floor, Building D2, Phase III, Software New Town, No. 8 Huacheng Avenue, East Lake High-tech Development Zone, Wuhan, Hubei Province, China
MaxCard:
CAS NO.1511511-44-6
1(10.0-10000)Milligram
We supply over 20000 types of spot impurity reference materials, with sufficient supply and same day delivery to meet customers' urgent needs for replenishment at any time. The company has its own research and development center and laboratory, and the team members have over ten years of experience in developing drug impurity reference standards. Our website www.molcoo.com covers over 98% of cutting-edge generic drug projects, with complete structural formulas that greatly save customers time in impurity structure analysis and inference. All products undergo strict quality control testing and provide relevant information such as COA, H-NMR, C-NMR, MS/GC-MS, HPLC/GC purity, QNMR quantification, TGA thermogravimetric analysis, IR infrared, UV ultraviolet, two-dimensional (COSY, NOESY, HMBC, HMQC), etc. These structural confirmation spectra ensure quality and reliability. Our products have a wide range of categories, fast delivery time, good quality, and low prices, which can quickly solve various customer needs such as replenishment and consistency evaluation.
Pregabalin Impurity 62;1511511-44-6
Product Information
Product Code: P006062
English Name: Pregabalin Impurity 62
English Alias: 2-(4-isobutyl-2-oxopyrrolidin-1-yl)acetic acid
CAS No.:1511511-44-6
Molecular Formula: C??H??NO?
Molecular Weight: 199.25
Advantages
High-Purity Reference Standard: As a reference standard for Pregabalin Impurity 62, its structure is confirmed by NMR and MS with ≥98.5% purity (HPLC), suitable for pharmaceutical impurity analysis and quality control.
Good Stability: Stored at 2-8°C in the dark, it has a shelf life of 24 months, with <1% degradation per month in solution (e.g., methanol), ensuring reliable detection data.
Applications
Impurity Detection: Used for HPLC/LC-MS detection of Impurity 62 in Pregabalin API and formulations, controlling impurity content ≤0.1% (refer to ICH Q3A).
Process Optimization: In Pregabalin synthesis, monitor the generation of this impurity during the cyclization stage, reducing its content to below 0.05% by adjusting reaction pH (controlled at 8.0-8.5) and temperature (≤50℃).
Stability Studies: As a degradation product standard in acid/alkali stress tests, validates method specificity and evaluates drug degradation pathways in pH 1.2/6.8 buffers.
Background Description
Pregabalin, a γ-aminobutyric acid (GABA) analog, is used to treat epilepsy, neuropathic pain, and other conditions. During its synthesis, Impurity 62 may arise from residual raw materials or cyclization side reactions. This impurity's pyrrolidinone ring structure may affect drug safety and efficacy. FDA's Guidance for Industry: Impurities in Drug Substances and Drug Products requires strict control of such heterocyclic impurities, driving the use of high-purity reference standards.
Research Status
Detection Technology: UPLC-MS/MS is used with a C18 column (1.7μm, 2.1×100mm) and 0.1% formic acid water-acetonitrile gradient elution, completing separation within 1.2 minutes with a detection limit of 0.008 ng/mL, 5 times more efficient than traditional HPLC.
Formation Mechanism: Mainly originates from the substitution reaction of 4-isobutyl-2-pyrrolidinone with chloroacetic acid, promoted by excessive raw materials or prolonged reaction time. Using potassium carbonate as a base and controlling reaction time within 3 hours reduces impurity content from 0.7% to 0.03%.
Safety Evaluation: In vitro experiments show an IC50 of 50μM on SH-SY5Y cells (Pregabalin API: 200μM), indicating low potential neurotoxicity, but EMA still sets its permissible daily exposure (PDE) ≤3μg, leading to a regulatory limit of ≤0.1% in drug standards.